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Background: Platelet hyperreactivity is a factor which contributes towards increased risk of cardiovascular events in
adults with type 2 diabetes (T2DM). However, little is known about platelets’ disturbances among children with type
1 diabetes (T1DM). The aim of the study was to investigate whether platelets’ morphology or function are altered in
children with type 1 diabetes, potentially predisposing them to cardiovascular events in the future.
Methods: The study group consisted of 389 children with T1DM during the 2008–2010 period. Patients with acute
diabetes complications and ongoing infections were excluded from the study. An equinumerous (N = 389), age and
sex-matched control group was assembled from children undergoing routine, minor surgical procedures in the same
hospital. Platelet: count (PLT), mean volume (MPV), distribution width (PDW) and platelet large cell ratio (P-LCR) as well
as HbA1c levels were measured. For statistical analysis we used Chi-square tests, the student’s t-test, one-way analysis
of variance (ANOVA), the Pearson’s correlation coefficient and linear regression models in order to adjust for covariates.
Results: MPV, PDW and P-LCR were significantly higher among children with diabetes in comparison with the control
group (MPV 10.47+/−0.85 fL vs 10.23+/−0.94 fL, p = 0.0007; PDW 12.09+/−1.80% vs 11.66+/−1.90%, p = 0.0032; P-LCR
28.21+/−6.15% vs 26.29+/−6.38%, p < 0.0001). PLT however, were shown to be similar (263.55+/−60.04 vs 268.77+/−65.78
103/μl; p = 0.5637). In both cases and controls age was inversely correlated with platelet count (for study group: r = −0.30,
p < 0.0001; for control group: r = −0.34, p < 0.0001), positively correlated with MPVs (r = 0.20, p < 0.0001; r = 0.26, p < 0.0001),
PDW (r = 0.25, p < 0.0001 and r = 0.24, p < 0.0001) and P-LCR (r = 0.26, p < 0.0001; r = 0.26, p < 0.0001). After adjustment for
confounding factors, higher platelet counts were associated with poorer metabolic control (beta = 0.20; 0.0001).
Conclusions: Platelets of paediatric patients with T1DM show morphological evidence of hyperreactivity (higher MPV,
PDW and P-LCR), while poorer metabolic control increases their number potentially predisposing the patients to future
cardiovascular events.
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Type 1 diabetes mellitus (T1DM) is the most common
metabolic disease among children, adolescents and young
adults and its incidence rate is still rapidly increasing [1].
As the onset of the disease occurs in early life, the afflicted
are at great risk of developing cardiovascular disease as a
complication of diabetes. Those long-term complications
are the leading cause of premature mortality in this group* Correspondence: wojciech.mlynarski@umed.lodz.pl
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unless otherwise stated.of patients [2,3]. The majority of ischemic events - occur
due to intravascular thrombosis. This is a state in which
subtle equilibrium between pro- and antithrombotic mech-
anisms is disrupted and the balance is shifted to favour
platelet aggregation and adhesion [4]. The main abnormal-
ity observed in diabetic platelets is their hypersensitivity
to agonists which leads to their hyperreactivity. It has
been shown that platelets obtained from patients suffering
from diabetes expressed augmented adhesiveness and ag-
gregation both spontaneous and in response to stimulat-
ing agents [5]. Currently available reports have shownentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with an elevated frequency of vascular complications in
adult patients with type 2 diabetes (T2DM) [4,6]. Based
on these observations large clinical trials were undertaken
and resulted in the introduction of the antiplatelet drugs
as a form of primary prevention in those patients [4].
Mean platelet volume (MPV) is considered as a marker
of platelet function. This is based on the fact that the larger
platelets are younger, contain more dense granules and
thus produce more thromboxane A2 [7]. In vitro studies
showed that increased MPV was associated with greater
aggregation in response to ADP and collagen [8]. Larger
platelets are more sensitive to platelets’ stimulants are thus
are more rapidly recruited to thrombus formation [9]. Tak-
ing into consideration aforementioned facts platelet size
is thought to be indirect indicator of platelet activity
and thus an important factor in micro- and macrovascu-
lar diabetes complications [10]. Higher MPV was noted in
people with both T1DM and T2DM and these alterations
are connected with metabolic control [10,11]. However
the influence of metabolic control on platelet morphologic
parameters, especially in patients with T1DM, is still
unclear and several studies have yielded ambiguous data
[12,13]. Studies concerning the link between platelet
morphology or function alteration and diabetes were most
often conducted on adult populations with T2DM. Our
study was aimed to compare morphological platelet pa-
rameters – as the indirect indicators of platelet activity -
between children with T1DM and their healthy peers.
Additionally, we wanted to correlated platelet morphology
parameters with glycated haemoglobin level.
Methods
Study group
The study group were children with T1DM treated with
insulin in the Department of Paediatrics, Oncology,
Haematology and Diabetology between years 2008–
2010. The study was approved by the institutional Ethics
Committee of the Medical University of Lodz and car-
ried out in compliance with the Helsinki Declaration.
Written parental consent for participation of their chil-
dren in the study was obtained. All patients were treated
intensively with multiple daily insulin injections (MDI)
or continuous subcutaneous insulin infusions (CSII).
Criteria for inclusion were set as: complete blood count
and HbA1c measurement performed on the same day,
duration of diabetes longer than 6 months and age lower
than 18 years. Patients with: known monogenic dia-
betes, acute complications of diabetes (severe hypoglycaemia,
diabetic ketoacidosis – defined according to International
Society of Pediatric and Adolescent Diabetes Guidelines
2014 [14,15]), ongoing infectious disease or children
treated with lipid-lowering or non-steroid anti-inflammatory
agents were excluded from the study group. Acute infectionin the control group was ruled out on the basis on elevated
CRP protein (>5 mg/L) results or elevated leukocyte count
(>11.000/μl). Patients with PLT (platelet counts) higher
than 500 or lower than 100 (103/μl) were excluded from
the study. In the study group acute complications of dia-
betes or infection were excluded on the basis of medical
records from our Department.Control group
The control group constituted of non-diabetic, healthy
children with blood count results who underwent minor,
planned surgical procedures in our hospital in 2008–
2010. Patients with infection or comorbidities, which
may affect significantly complete blood count parame-
ters, were excluded from the study. The control group
was age- and sex-matched to the study group.Data collection
Platelets morphology parameters e.g. platelet count (PLT),
mean platelet volume (MPV), platelet distribution width
(PDW) and platelet large cell ratio (P-LCR) were extracted
from routinely performed complete blood count results.
The blood counts were performed with Pentra XLR (Horiba
ABX Ltd., Warsaw, Poland).
HbA1c measurements were performed with the VARIANT
device (Bio-Rad Laboratories, Hercules, CA, USA). Results of
HbA1c measurements were in line with NGSP (National
Glycohaemoglobin Standardization Program) guide-
lines on HbA1c measurement standardization as meeting
the DCCT standard (http://www.ngsp.org/docs/methods.
pdf).Statistical analysis
Nominal variables were given as numbers with appropri-
ate percentage whereas continuous variables were pre-
sented as means with standard deviation. Chi-square tests
were used to test associations between categorical vari-
ables. For pairwise comparisons of continuous variables,
the student’s t-test was used. For multi-group comparisons
one-way analysis of variance (ANOVA) was used. Post-hoc
between group comparison were performed with Tukey’s
test. Correlations were assessed using the Pearson’s correl-
ation coefficient. Multivariate analyses were performed
using linear regression models in order to adjust for covari-
ates. P values lower <0.05 was considered as statistically
significant. The sample size was planned using power ana-
lysis methods to allow us to detect differences between
groups greater than 0.2 of one standard deviation with stat-
istical power of 0.8. This estimation suggested equinumer-
ous groups of at least 384 individuals. Statistical analysis
was performed with usage of STATISTICA 10.0 software
(Statsoft, Tulsa, OK, USA).
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Baseline characteristics of the study groups were shown
in Table 1. The study and control groups did not differ
in terms of age and sex. In both groups age was nega-
tively correlated with patient’s platelet counts (for study
group: r = −0.30, p < 0.0001; for control group: r = −0.34,
p < 0.0001), positively correlated with MPVs (r = 0.20, p
< 0.0001; r = 0.26, p < 0.0001), PDW (r = 0.25, p < 0.0001
and r = 0.24, p < 0.0001) and with P-LCR (r = 0.26, p <
0.0001; r = 0.26, p < 0.0001) (Figure 1).
Comparison of the study and control group
Mean platelet volume was significantly higher among chil-
dren with diabetes in comparison with the control group
(MPV 10.47+/−0.85 fL vs. 10.23+/−0.94 fL, p = 0.0007).
Additionally, platelet distribution width was higher in the
in study group than in controls (PDW 12.09+/−1.80% vs.
11.66+/−1.90%, p = 0.0032). This could be associated with
greater population of the larger platelets in diabetic chil-
dren, which were more numerous in the study group
(PLC-R 28.21+/−6.15% vs. 26.29+/−6.38%, p < 0.0001).
We did not find a significant difference in PLT between
study and control group (263.55+/−60.04 103/uL vs.
268.77+/−65.78 103/uL; p = 0.5637) (Table 2). Although
the differences became visible when the group with
T1DM was divided into well and poorly controlled disease
and then compared with control group (below 6.5% of
Hb1Ac for good metabolic control according to American
Diabetes Association standards 2014 [16]). Surprisingly
PLT was the lowest in patients with good metabolic con-
trol (255.08+/−53.93 103/uL), PLT was similar in poorly
controlled patients and control group (269.84+/−60.08
103/uL vs 271.39+/−63.39 103/uL respectively; p ANOVA=
0.0563). In case of other platelet parameters (MPV, PDW,
P-LCR) the lowest values were observed in the control
group while the highest in the poorly controlled subgroup
of patients with T1DM (Figure 2). This suggested that
well-controlled diabetic patients have platelet morphology
parameters similar to healthy children.Table 1 Clinical characteristics of the studied and control
groups
Study group Control group p value
Boys/All (%) 222/389 (57.07%) 207/389 (53.21%) 0.2794
Age [years] 12.76+/−3.81 12.33+/−4.34 0.1467
Treatment type
[CSII/all (%)]









Values are presented as numbers with percentages or means with standard
deviations. CSII – continuous subcutaneous insulin infusion, HbA1c – glycated
haemoglobin, NA – not applicable.Influence of metabolic control on platelet morphology
To evaluate the influence of HbA1c on platelet parameters
we built multivariate regression models to adjust correla-
tions for patient’s age, sex, diabetes duration and diabetes
treatment type (Table 3). After adjustment for covariates,
only PLT was shown to positively correlate with metabolic
control of diabetes (B = 0.20; p < 0.0001). All platelet pa-
rameters showed significant correlations with the duration
of diabetes. However this effect was due to correlation of
diabetes duration with patients’ age.
Discussion
Our study showed that children with T1DM have ele-
vated platelet volume, wider platelet size distribution
width and increased percentage of large platelets. We also
found that platelet count was significantly associated with
metabolic control. The positive correlation between PLT
and HbA1c remained significant after adjustment for con-
founding factors.
Very little is known about correlation of platelet mor-
phologic parameter with metabolic control of the T1DM
in children. A study by Pirgon et al. focused on relation
between MPV and HbA1c, but no significant correlation
was found [17]. The authors found also that MPV was
higher in the group of patients with T1DM in compari-
son with healthy children, which is in agreement with
the results of our study. Both studied populations were
in similar age (7.9+/−4.2 years and control group was
7.4+/−3.2 years). The study however was conducted on
limited number of patients (N = 56) and the results were
not adjusted for patients’ age and sex. In our study MPV
in patients with diabetes was only slightly increased
(10.47+/−0.85 fL vs. 10.23+/−0.94), but we cannot rule
out that this might have clinical implications. Studies
conducted on patients with T2DM found significant re-
lationship between micro- and macrovascular complica-
tions and MPV [18,19]. This had lead us to hypothesize
that even a small increase of MPV might reflect a higher
propensity for vascular complications in patients with dia-
betes than healthy peers. In our study the highest MPV
was observed in poorly controlled patients which supports
abovementioned hypothesis.
Our recent ongoing study provided information that
higher PLT among children with T1DM was connected
with shorter time of thrombus formation (unpublished
data). Taken into consideration that PLT was found to be
independently associated with HbA1c we suppose that
poorly controlled T1DM in children have increased plate-
let activity.
The underlying cause of the observed differences may
be related to several factors, most notably platelet function
or their turnover. Diabetes mellitus is a prothrombotic
state characterized by platelet hyperreactivity, hyperag-
gregability, enhanced thrombinogenesis and reduced
Figure 1 Correlations of platelet parameters with age in the study and control groups: A/B – Platelet count; C/D – mean platelet
volume; E/F – platelet distribution width; G/H – platelet large cell ratio.
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Table 2 Comparison of platelet parameters between the study groups
Study group Control group p p adjusted
for age and sexMean+/−Std. Dev. Mean+/−Std. Dev.
MPV [fL] 10.47+/−0.85 10.23+/−0.94 0.0003 0.0007
PLT [103/uL] 263.55+/−60.04 268.77+/−65.78 0.2482 0.5637
PDW [%] 12.09+/−1.80 11.66+/−1.90 0.0012 0.0032
P-LCR [%] 28.21+/−6.15 26.29+/−6.38 <0.0001 <0.0001
MPV – mean platelet volume; PLT – platelet count; PDW – platelet distribution width; P-LCR – platelet large cell ratio.
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tients with diabetes are more active than in healthy popu-
lation. Even in the absence of vascular injuries, the
platelets have greater expression of the glycoprotein IIb/
IIIa receptor, which is the final common pathway of plate-
let activation. A recent study concluded that advanced gly-
cation end products might be the source of altered
platelet function [20]. Thus platelets in patients with dia-
betes respond to even subthreshold stimuli which leads to
faster exhaustion and consumption and, in turn, ends inFigure 2 Comparison of platelets morphological parameters between
Horizontal lines represent means with standard deviation: A – Platelet coun
distribution width (p = 0.0002); D – platelet large cell ratio (p < 0.0001). Forreleasing fresh, hyperreactive platelets [21]. Therefore
higher MPV, connected with platelet activity, is often con-
sidered as a hallmark of impaired thrombopoiesis in dia-
betes mellitus [9,22]. It has been shown that platelet
population in patients with diabetes exhibits pronounced
bimodality i.e. extreme dimensions with an increased
number of very large and very small platelets [23]. This
was reflected by higher PDW values observed in our
patients. The platelet size is also connected with its
life time – small platelets are regarded as older, havinglow (≤6.5%) and high (>6.5%) HbA1c group and control group.
t (p = 0.0563); B – mean platelet volume (p = 0.0004); C – platelet
post-hoc analyses significant results were indicated with stars.
Table 3 Multivariate regression model results testing for the association of platelet parameters and metabolic control
Diabetes duration HbA1c
r, p value Adjusted beta, p value r, p value Adjusted beta, p value
MPV 0.15, 0.0026 0.06, 0.2953 0.04, 0.4249 −0.03, 0.5703
PLT −0.11, 0.0230 0.04, 0.4352 0.10, 0.0484 0.20, <0.0001
PDW 0.14, 0.0059 0.01, 0.7978 0.07, 0.1929 −0.01, 0.7913
P-LCR 0.17, 0.0007 0.06, 0.2726 0.05, 0.2940 −0.03, 0.5746
The effects shown were adjusted for patients’ age, sex and type of treatment. Poorer metabolic control was significantly associated with higher platelet counts.
MPV – mean platelet volume; PLT – platelet count; PDW – platelet distribution width; P-LCR – platelet large cell ratio; Beta – partial correlation coefficient.
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platelets are considered younger and more active [24].
Thus, bimodal distribution of platelet size may be indica-
tive of increased platelet turnover. We observed the high-
est proportion of large, most active platelets in poorly
controlled patients with T1DM.
One could also hypothesise that the observed alter-
ations are the result of primary disorder of platelet pre-
cursors, megakaryocytes. Some authors have stated that
peripheral platelets are activated in newly diagnosed or
even prediabetic patients which could mean that every-
thing is determined at the level of progenitor cells [25].
Many studies report that cytokines such as interleukin-3,
6 and 11 influence megakaryocyte ploidy and may lead
to production of more reactive platelets [26,27]. This idea
is supported by higher levels of proinflammatory IL-6 in
children with T1DM than in healthy peers [28]. Moreover,
megakaryocyte functions might be impaired in case of
long lasting low glucose levels which are present in well
controlled patients and that might result in reduced plate-
let production. This hypothesis might explain why lower
PLT counts were found in the subgroup of patients with
low HbA1c levels.
The major clinical question is whether one should coun-
teract increased platelet activity in paediatric patients with
T1DM. Maybe good metabolic control in those patients is
sufficient to prevent cardiovascular complications and no
additional treatment is needed. However recent type re-
ports do not support this hypothesis. In a metaanalysis
performed on 2254 patients with 1 diabetes, intensive gly-
cemic control did not affect all-cause mortality or cardio-
vascular mortality [29]. Nevertheless, we still wait for final
answer from DCCT/EDIC which even after 30 years of
data collection does not provide a conclusive result [30].
It should be stated that our study has several limita-
tions. Metabolic control was assessed by HbA1c, which
corresponds to average glycaemia from the three preceding
months. However, platelet lifetime is about 7 to 10 days,
which may have affected the observed correlations. One
could thus suggest to use a substance such as fructosamine
with a shorter half-life time period instead. Unfortunately
this marker was not routinely used in our Department
throughout the study period. Although we excludedpatients with severe infections there is still a possibil-
ity that minor infections could affect the platelet pa-
rameters. Additionally patients from the control group
underwent minor scheduled surgical procedures and the
stress conditions connected with this situation might
affect the platelet parameters. Another issue which should
be taken into consideration in this age group is the matter
of pubescence. We countered that by adjusting for pa-
tients’ age and sex, but individual levels and potential
impact of sex hormone levels on megakaryocytes and
platelets are unknown to us.
We believe that metabolic control may be connected
with platelet parameters and functions in patients with
T1DM. The abovementioned platelet alterations might
be associated with diabetes complications particularly
because this group of patients is exposed for hypergly-
caemia, oxidative stress and proinflammatory state from
the early years. The results of our study support the the-
ory that platelet function is altered even in young pa-
tients with diabetes potentially contributing to increased
cardiovascular risk later on.
Conclusions
Despite the abovementioned limitations to our knowledge
our study is the firstly major report presenting the impact
of T1DM on commonly measured platelet parameters in
the paediatric population. Further studies are needed as it
remains to be evaluated whether antiplatelet drugs may
help to safeguard patients with T1DM against future car-
diovascular diabetes complications.
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